Hatching Pandion

Why Polaris built its own platform for immunology play Pandion

After scouring academia for novel treatment approaches to autoimmune and inflammatory diseases and coming up empty-handed, Polaris Partners formed Pandion Therapeutics Inc. to develop its own platform from the ground up.

Backed with a $58 million series A round, Pandion

Read the full 397 word article

User Sign In